No Data
The current cycle of Traditional Chinese Medicine materials is entering a downturn phase, and pharmaceutical companies may face a cost "turning point."
In the second half of 2024, the prices of Traditional Chinese Medicine materials are expected to decline overall; the semi-annual and third quarter reports of this year show that the gross margin of some Chinese Patent Medicine listed companies has significantly decreased, indicating a notable impact of the fluctuation in Traditional Chinese Medicine material prices on costs. However, with the retreat in Traditional Chinese Medicine material prices, production costs for companies will also decrease.
On December 19, PHARMARON (03759.HK) spent 5.4567 million Hong Kong dollars to repurchase 0.4 million shares.
On December 19, Gelonghui announced that PHARMARON (03759.HK) spent HKD 5.4567 million to repurchase 0.4 million shares on December 19, 2024, with a repurchase price of HKD 13.48-13.8 per share.
On December 18, PHARMARON (03759.HK) spent 5.5632 million HKD to repurchase 0.4 million shares.
Glory Financial reported on December 18 that PHARMARON (03759.HK) announced it will spend 5.5632 million Hong Kong dollars to repurchase 0.4 million shares on December 18, 2024, with a buyback price of 13.76-14 Hong Kong dollars per share.
On December 17, PHARMARON (03759.HK) spent 2.763 million Hong Kong dollars to repurchase 0.2 million shares.
Gelonghui, December 17, PHARMARON (03759.HK) announced that on December 17, 2024, it spent 2.763 million Hong Kong dollars to repurchase 0.2 million shares, with a repurchase price of 13.7-13.98 Hong Kong dollars per share.
Sinolink: The end of year centralized purchasing expectations are gradually being cleared, and the pharmaceutical sector行情 is expected to gradually start.
The pharmaceutical Sector is currently in a process of a triple reversal in performance, policies, and funding, with full confidence in the recovery of revenue profit growth and market resurgence of listed companies in the Sector by 2025.
A share investment lightning rod on December 10: Shareholders Yinkun Company and Longxin Construction plan to reduce their total holdings by no more than 2%
PHARMARON's major shareholder, Xin Zhongkang, and its concerted actors completed the Shareholding reduction of 16 million Stocks; two shareholders of Zhi Xin Precision plan to collectively reduce no more than 3.0375% of their Shares; Shenzhen SDG Service shareholders, Yinkun Company and Longxin Construction, plan to collectively reduce no more than 2% of their Shares; Wuxi Zhenhua's shareholder Wuxi Jinfengyu plans to reduce 3% of its Shares; Hainan Poly Pharm is currently under investigation by the Securities Regulatory Commission, and the Stocks face the risk of being subjected to significant illegal delisting; Zhejiang Yiming Food's Stocks have been suspended for 10 consecutive Trading days, facing the risk of a significant decline in the short term; Tibet Summit Resources received a warning letter from the Tibet Securities Regulatory Bureau.
Expand
No Data
102884128 : getting disappointed with this counter. every day drop.